Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease

X
Trial Profile

A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olinciguat (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Acronyms STRONG-SCD
  • Sponsors Cyclerion Therapeutics; Ironwood Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2020 This trial has been Discontinued in United Kingdom, according to European Clinical Trials Database record.
    • 14 Oct 2020 According to a Cyclerion Therapeutics media release, Results did not demonstrate adequate activity to support further internal clinical development. Company intends to complete its analysis of the study results and present or publish them in a future forum.
    • 14 Oct 2020 Results presented in a Cyclerion Therapeutics Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top